This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunitiesAbout the Project
The aim of the project is to pre-clinically validate a newly developed monoclonal antibody for neuroblastoma therapeutics. The anti-LGR5 antibody (called BNC101) has been originally developed to target colon cancer stem cells. We will use the reagent in experiments whose primary objective is to evaluate the ability of the antibody to induce cancer regression in vitro and in vivo, especially in the context of patient-derived xenografts (PDX). A secondary aim is to clarify mechanisms of action, safety and identify biomarkers that predict clinical response. The project is ideally suited to a student with an MD or first or upper second undergraduate degree in cell biology, molecular biology or pharmacology. Familiarity with cancer cell cultures and basic biochemical and molecular techniques is also essential.
Funding Notes

Search Suggestions
Based on your current searches we recommend the following search filters.
Check out our other PhDs in London, United Kingdom
Check out our other PhDs in Medical / Clinical Science
Start a new search with our database of over 4,000 PhDs

PhD Suggestions
Based on your current search criteria we thought you might be interested in these.
Cleaner coal technology - Developing new predictive tools for improving the combustion processes for coal/biomass fuels
University of Sheffield
Developing new strategies for the treatment of metabolic diseases
Hong Kong Baptist University
What really makes a bacterial lipoprotein a real lipoprotein? Important implications for developing or improving lipoprotein-based vaccines
University of Nottingham